ストックスクリーナーアプリを入手
1.11
1.77%
-0.02
前日終値:
$1.13
開ける：
$1.15
24時間の取引高:
35,530
Relative Volume:
0.33
時価総額：
$12.57M
収益：
-
当期純損益:
$-9.70M
株価収益率:
-1.0091
EPS:
-1.1
ネットキャッシュフロー:
$-8.57M
1週間 パフォーマンス:
-4.31%
1か月 パフォーマンス:
+2.78%
6か月 パフォーマンス:
-63.84%
1年 パフォーマンス:
-72.93%
1日の値動き範囲:
$1.07
$1.15
1週間の範囲:
$1.07
$1.21
52週間の値動き範囲:
$0.95
$5.99
Marker Therapeutics Inc Stock (MRKR) Company Profile
名前
Marker Therapeutics Inc
セクター
電話
(713) 400-6400
住所
2450 HOLCOMBE BLVD, HOUSTON, TX
MRKR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRKR
Marker Therapeutics Inc
|
1.11 | 12.42M | 0 | -9.70M | -8.57M | -1.10 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Marker Therapeutics Inc Stock (MRKR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-05 | 開始されました | Canaccord Genuity | Buy |
| 2021-03-25 | 開始されました | Piper Sandler | Overweight |
| 2021-03-19 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-05-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2019-05-30 | 開始されました | ROTH Capital | Buy |
| 2019-03-01 | 開始されました | Janney | Buy |
| 2018-12-03 | アップグレード | Piper Jaffray | Neutral → Overweight |
すべてを表示
Marker Therapeutics Inc (MRKR) 最新ニュース
Marker Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Hematopoietic stem cell transplantation Market: Investment - openPR.com
Peptide Cancer Vaccine Market Set to Witness Significant Growth - openPR.com
Marker Therapeutics (MRKR) Expected to Announce Earnings on Wednesday - Defense World
Peptide Cancer Vaccine Market Is Booming Worldwide | Marker - openPR.com
Matinas Biopharma (NYSE:MTNB) versus Marker Therapeutics (NASDAQ:MRKR) Head to Head Review - Defense World
Altesa BioSciences announces Katharine Knobil, M.D. as Chief Medical Officer - PR Newswire
Marker Therapeutics Advances T Cell Therapies in 2024 - TipRanks
LPL Financial LLC Acquires New Holdings in Marker Therapeutics, Inc. (NASDAQ:MRKR) - Defense World
Acute Myeloid Leukemia Drugs Market 2034: EMA, PDMA, FDA - openPR.com
Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results - ADVFN
FibroBiologics opens cell therapy manufacturing space ahead of clinical trials - The Business Journals
Acute Myeloid Leukemia Treatment Market 2034: Clinical Trials, - openPR.com
Brookline Capital Management Comments on MRKR Q1 Earnings - Defense World
Marker Therapeutics (NASDAQ:MRKR) Receives Strong-Buy Rating from WBB Securities - The AM Reporter
Brookline Capital Management Estimates MRKR FY2026 Earnings - Defense World
Marker Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Breakthrough: New Alzheimer's Drug Cuts Key Brain Marker by 15%University Study Reveals - Stock Titan
Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference - GlobeNewswire
MRKR stock touches 52-week low at $1.12 amid market challenges - Investing.com
Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference - The Manila Times
Revolutionary MAR-T Cell Therapy: Marker CEO Reveals Latest Advances in Solid Tumor Treatment - Stock Titan
Marker Therapeutics Advances MT-601 with Promising Results and Strategic Funding - TipRanks
Breakthrough: Marker's Lymphoma Drug Shows 78% Success Rate as Company Raises $29M - Stock Titan
Marker Therapeutics, Inc. SEC 10-K Report - TradingView
Form 10-K Marker Therapeutics, For: Dec 31 - StreetInsider
Marker Therapeutics stockholder vote clears warrant issuance By Investing.com - Investing.com Australia
Marker Therapeutics stockholder vote clears warrant issuance - Investing.com
These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company
Marker Therapeutics (MRKR) to Release Earnings on Monday - Defense World
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
MRKR stock touches 52-week low at $1.35 amid market challenges - Investing.com Australia
MRKR stock touches 52-week low at $1.35 amid market challenges By Investing.com - Investing.com South Africa
Canaccord Genuity Group Initiates Coverage on Marker Therapeutics (NASDAQ:MRKR) - Defense World
Pre-market Movers: PRFX, BJDX, TARA, PBM... - RTTNews
This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Canaccord Genuity Initiates Coverage of Marker Therapeutics (MRKR) with Buy Recommendation - Nasdaq
Marker Therapeutics initiated with a Buy at Canaccord - TipRanks
MRKR stock touches 52-week low at $1.45 amid market challenges - Investing.com India
MRKR stock touches 52-week low at $1.45 amid market challenges By Investing.com - Investing.com South Africa
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - GlobeNewswire
Will Marker Therapeutics Reveal New Clinical Data at Upcoming Cell Therapy Conference? - StockTitan
MRKR stock touches 52-week low at $1.48 amid market challenges - Investing.com India
MRKR stock touches 52-week low at $1.48 amid market challenges By Investing.com - Investing.com South Africa
Marker Therapeutics Inc (MRKR) 財務データ
収益
当期純利益
現金流量
EPS
Marker Therapeutics Inc (MRKR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| New Enterprise Associates 16, | 10% Owner |
Dec 23 '24 |
Buy |
3.20 |
554,250 |
1,773,600 |
1,625,678 |
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):